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Abstract
The non-classical Human Leukocyte Antigen G (HLA-G) differs from classical HLA class I
molecules by its low genetic diversity, a tissue-restricted expression, the existence of seven
isoforms, and immuno-inhibitory functions.
Most of the known functions of HLA-G concern the membrane-bound HLA-G1 and soluble HLA-
G5 isoforms, which present the typical structure of classical HLA class I molecule: a heavy chain
of three globular domains α1–α2–α3 non-covalently bound to β-2-microglobulin (Β2M) and a
peptide. Very little is known of the structural features and functions of other HLA-G isoforms or
structural conformations other than Β2M-associated HLA-G1 and HLA-G5.
In the present work we studied the capability of all isoforms to form homomultimers, and
investigated whether they could bind to, and function through the known HLA-G receptors
LILRB1 and LILRB2. We report that all HLA-G isoforms may form homodimers, demonstrating
for the first time the existence of HLA-G4 dimers. We also report that the HLA-G α1–α3
structure, that constitutes the extracellular part of HLA-G2 and HLA-G6, binds the LILRB2
receptor but not LILRB1. This is the first report of a receptor for an HLA-G truncated isoform.
Following up on this finding, we show that the α1–α3-Fc structure coated on agarose beds is
tolerogenic and capable of prolonging the survival of skin allografts in B6-mice and in a LILRB2-
transgenic mouse model. This study is the first proof of concept that truncated HLA-G isoforms
could be used as therapeutic agents.
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INTRODUCTION
Human leukocyte antigen G (HLA-G) [1,2] is a non-classical HLA class I molecule which
transcript was first identified in choriocarcinoma cells [3]. Since then, HLA-G has been
termed “non-classical” because it differs from classical HLA class I molecules by its genetic
diversity, expression, structure and functions. HLA-G is characterized by a low
polymorphism [4,5], and its expression is mainly restricted to trophoblast cells [6], adult
thymic medulla [7], and stem cells [8–10]. However, HLA-G neo-expression may be
induced in pathological conditions such as cancers [11], transplantation [12], multiple
sclerosis [13], inflammatory diseases [14] and viral infections [15,16].
The alternative splicing of the HLA-G primary transcript can generate 7 different isoforms,
four being membrane-bound (HLA-G1, G2, G3, G4) and three being soluble (HLA-G5, G6,
G7). As shown in Figure 1, HLA-G1 and HLA-G5 isoforms present the typical structure of a
classical HLA class I molecule, i.e. a heavy chain of three globular domains non-covalently
bound to β-2-microglobulin (B2M) and a peptide, whereas the other isoforms are shorter,
lacking one or two domains of the heavy chain, and should not bind B2M. It has to be noted
that, the α1 domain is present in all HLA-G isoforms.
No stimulatory function has been reported to date for HLA-G, even responses to allogeneic
HLA-G. However, this molecule exerts an immuno-inhibitory function through direct
binding to three inhibitory receptors: ILT2/CD85j/LILRB1, ILT4/CD85d/LILRB2 and
KIR2DL4/CD158d. LILRB1 is expressed by B cells, some T cells, some NK cells, and all
monocytes/dendritic cells [17], whereas LILRB2 is myeloid specific and its expression is
restricted to monocytes/dendritic cells [18]. KIR2DL4 is a specific receptor for HLA-G,
only expressed by the CD56bright subset of NK cells [19]. Through interactions with these
receptors, HLA-G1 inhibits the cytolytic function of uterine and peripheral blood NK cells
[20], the antigen-specific cytolytic function of cytotoxic T lymphocytes [21], the
alloproliferative response of CD4+ T cells [22,23], the proliferation of T cells and peripheral
blood NK cells [24–26], and the maturation and function of dendritic cells [27–29].
Furthermore, HLAG is capable of inducing the generation of suppressive cells
[30,31,27,32].
HLA-G1 and HLA-G5 are the isoforms that were studied the most extensively, particularly
with respect to their structures and their interactions with the inhibitory receptors LILRB1
and LILRB2. HLA-G1 and HLA-G5 (HLA-G1/5) can form dimers [33,34] through
disulphide bonds between unique cysteine residues at positions 42 (Cys42-Cys42), within
the α1 domain. It was shown that dimers of Β2M-associated-HLA-G1 bind LILRB1 and
LILRB2 with higher affinity than monomers (Kd of monomers vs dimers were calculated at
3.5 µM vs 0.0067 µM for LILRB1, and 15 µM vs 0.75 µM for LILRB2) [35]. This increased
affinity of dimers is due to an oblique orientation that exposes the LILRB1- and LILRB2-
binding sites of the α3 domain, making it more accessible to the receptors. Both LILRB1
and LILRB2 bind the HLA-G α3 domain at the level of F195 and Y197 residues. However,
LILRB1 interacts preferentially with B2M-associated HLA-G, whereas LILRB2
predominantly interacts with B2M-free HLA-G [35]. This difference is very relevant
because HLA-G1 and HLA-G5 have been detected as B2M-free heavy chains at the cell
surface and in culture supernatants of HLA-G expressing cells [36]. Furthermore, B2M-free
HLA-G heavy chains may be the main structures produced by human villous trophobast
cells [37].
Thus, it seems obvious that HLA-G structure variation plays a role in the biological function
of HLAG and its regulation. Yet the full extent of HLA-G structural diversity remains
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unknown [2]. In fact, since all HLA-G isoforms have the Cys42 residue, they all should be
able to dimerize, as it was shown for HLA-G1 [33] and HLA-G2 and -G6 [38].
Furthermore, even though the structure of B2M-associated HLA-G1 is known [39] and the
structural parameters of its association with LILRB1 and LILRB2 have been described
[35,40], nothing is certain concerning the structure of truncated isoforms or the receptors
they bind to.
Thus, we investigated the capability of all HLA-G isoforms to form dimers, and the
mechanism of action of the HLA-G2 and HLA-G6 isoforms (HLA-G2/6) (α1–α3 domains).
We were particularly interested in the α1–α3 structure because its expression has been
shown after heart transplantation and is indicative of graft better acceptance [12]. We also
investigated whether this isoform was actually capable of promoting allograft tolerance by
itself in vivo in an animal model.
Our results show that all isoforms, except for HLA-G3, can dimerize, and we report the
existence of the HLA-G4 dimers for the first time. Focussing on the α1–α3 structure (HLA-
G2 and -G6 isoforms), we demonstrate its binding to LILRB2 but not LILRB1. Finally we
demonstrate that the α1–α3:LILRB2 interaction is tolerogenic in vivo in an allogeneic skin
transplantation murine model.
MATERIALS AND METHODS
Cells lines and transfectants
M8 is an HLA-G-negative melanoma cell line. Transfectants were obtained by
electroporation as previously described in [41]. Transfectants used were named M8-HLA-
G1, M8-HLA-G2, M8-HLA-G3, M8-HLA-G4, M8-HLAG5, and M8-HLA-G6 according to
the HLA-G isoform cDNA transfected [42]. M8 cells transfected with the pcDNA3.1 vector
alone were used as a negative control cell line (M8-pcDNA).
The NKL line [43] is an NK cell line that endogenously expresses both KIR2DL4 and
LILRB1. This line will thereafter be referred to as NKL-LILRB1+. NKL-LILRB1+LILRB2+
are NKL-LILRB1+ cells transduced with a lentivirus containing the LILRB2 cDNA. The
phenotype of NKL-LILRB1+ and NKL-LILRB1+LILRB2+ cells with respect to LILRB1
and LILRB2 expression is shown in Supplemental Figure 1. As can be seen, both cell lines
express the LILRB1 receptor to the same extent, and LILRB2 expression is very high in
NKL-LILRB1+LILRB2+ cells whereas NKL-LILRB1+ cells do not express it.
Cells were maintained in RPMI 1640 medium supplemented with 10% inactivated FCS,
2mM L-glutamine, 1mg/ml gentamicin, and fungizone. HLA-G M8 transfectants were
selected in medium containing 100µg/ml Hygromycin B (Sigma, St. Louis, MO).
Recombinant proteins constructions and coated microspheres
Lentiviruses—HLA-G1 cDNA, HLA-G2 cDNA, and LILRB2 cDNA were amplified by
PCR and cloned into the pWPXL lentiviral vector (Addgene) from which GFP had been
removed by enzymatic restriction, generating the pWPXL-HLA-G1, pWPXL-HLA-G2, and
pWPXL-LILRB2 vectors.
Lentiviral particles were produced by triple-transfecting HEK293T cells by the calcium
phosphate method with pWPXL-HLA-G1, pWPXL-HLA-G2, or pWPXL-ILT4 vectors, the
packaging plasmid psPAX2, and the envelope plasmid pMD2.G (Addgene). The
supernatants containing lentiviral particles were harvested 48 h after transfection. K562 cells
were transduced with HLA-G1 or HLA-G2 lentiviral particles, and NKL-LILRB1+ cells
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were transduced with LILRB2 lentiviral particles. Cell surface expression of the transduced
molecules was verified by flow cytometry analysis using anti- HLA-G1 MEM/G-09-PE
(Exbio), anti HLA-G alpha1 domain 4H84 (Exbio), and anti-LILRB2-PE (Beckman
Coulter) mAbs, respectively.
HLA-G5-GST and HLA-G6-GST proteins—BL21-Gold Competent bacteria were
transformed with pGEX-6P-2-HLA-G5 or pGEX-6P-2-HLA-G6 following manufacturers
recommendations (GE-Healthcare). Bacteria were selected in 200µg Ampicilin-LB medium,
and cultured in antibiotic free-LB medium at 37°C at 200 rpm overnight (ON), until a
OD=0.6 was reached. They were then induced with 0.1 mM IPTG and cultured in the same
conditions for 3 hours. Culture was harvested and centrifuged at 3000g for 40 min. Pellets
were collected, and bacteria were lysed with 20 mM Tris-HCl pH=7.4, 1 mM PMSF buffer,
and centrifuged at 15000g for 30 min at 4°C. Pellets were treated with Urea 8 M in order to
dissolve inclusion bodies, and dialyzed against 50mM Tris-HCl, pH=7.5, 0.5 M NaCl, 2mM
MgCl2 buffer at 4°C overnight. Samples were purified by GSTrap columns following
manufacturer’s recommendations (GE-Healthcare).
α1–α3-Fc ***fusion protein—α1–α3 cDNA was cloned into the pFUSE-hFc1 vector
(Invitrogen). This pα1–α3-hFc construction was then transfected into HeLa Cells (ATCC).
The α1–α3-Fc proteins that were used in this report were culture supernatants of α1–α3-Fc-
transfected HeLa cells produced in DMEM, 10% FCS, 2mM L-glutamine.
For α1–α3-Fc-coated microsphere generation, 1×108 sulfate latex beads 4%w/v 5µm
(Invitrogen) were coated with 20µg/ml AffiniPure anti-human IgG Fc fragment (Jackson
ImmunoResearch) for 2 hours at 37°C followed by a 2-hour incubation with BSA (2 mg/
ml). After washing, the beads were incubated in culture supernatant containing 0.5µg/ml of
α1–α3-Fc fusion protein at 4°C for 16 hours. Subsequently, the beads were washed twice
with PBS. 5ml of HLA-G6-Fc fusion proteins (1µg/ml) were used for 5×106 sulfate latex
beads. As a negative control, sulfate latex beads were prepared in an identical manner except
that PBS or HeLa mock supernatant was used rather than α1–α3-Fc fusion protein-
containing supernatants.
Monoclonal Abs and flow cytometry analysis
The following mAbs were used: from R&D Systems: LILRB1-hFc and LILRB2-hFc; from
Exbio (Praha): PE-conjugated anti-HLA-G MEM-G/09 and anti-HLA-G 4H84; from Sigma:
goat-anti-mouse HRP and PE conjugated goat-anti-hFc; from Novus Biologicals: FITC-
conjugated anti-GST antibody; and from Beckman Coulter: PE-conjugated anti-LILRB1 and
PE-conjugated anti-LILRB2.
Lysis, Immunoprecipitation and Western blot analysis
Cell lysis—Cells were washed with PBS and then lysed in lysis buffer [50mM Tris
pH=7,5, 50mM iodoacetamide, 0,5% Chaps] at a concentration of 107 cells/ml.
Iodoacetamide at this concentration prevents post-lysis multimerisation of HLA Class I
molecules [44]. Lysates were then directly loaded into the gels or subjected to
immunoprecipitation.
Immunoprecipitation—Thawed lysates were incubated for 90 min at 4°C with protein G-
Sepharose beads coated with isotype control mAb. Precleared lysates were then
immunoprecipitated for 90 min at 4°C with protein G-Sepharose beads precoated with
LILRB2-Fc. Immunoprecipitates were washed three times with PBS. Proteins bound on
beads were divided into two aliquots; one was reduced (reducing condition) by β-
mercaptoethanol-containing Laemmli buffer (0.4% Sodium Dodecyl Sulfate, 5% Glycerol,
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1.67% β-Mercaptoethanol, 0.0067% Bromophenol Blue, 0.4% DTT, 20.8 mM Tris HCl,
pH=6.8) while the other was not reduced (Laemmli buffer without β-mercaptoethanol and
DTT).
Western blotting—Aliquots of total proteins from M8 transfectants (lysates) or proteins
immunoprecipitated from M8 transfectants were separated in 12% SDS-PAGE. The
amounts of lysates loaded were adjusted for each cell line to minimize non-specific
background. The gels were blotted onto nitrocellulose membranes (Hybond; Amersham,
Buckinghamshire, U.K.), and the membranes were blocked by a 2-hour incubation with PBS
containing 0.2% Tween 20 and 5% non-fat dry milk. The membranes were then probed
overnight at 4°C with the corresponding antibodies and washed in PBS containing 0.2%
Tween 20. The membranes were subsequently incubated for 1 hour at room temperature
with peroxidase-conjugated goat anti-mouse IgG Ab (Sigma), washed thoroughly, stained
with enhanced chemiluminescence reagent (Amersham), and exposed to X-ray film.
Cytometry-based HLA-G:LILRB interaction analysis
Luminex bead-based assay—In order to evidence HLA-G:LILRB interactions,
recombinant, HLA-G6- GST and control GST proteins were coated on Bio-Plex COOH
beads (Bio-Rad) using the Bio-Plex Amine Coupling kit (Bio-Rad) following the provider’s
recommendations. 2000 of these coupled beads were then incubated with sample for 90 min
at room temperature, and then again 60 min at room temperature in the presence of 20 µg/ml
of human IgG, LILRB1-Fc or LILRB2-Fc. Beads were then extensively washed, and
binding of control IgG, LILRB1-Fc, and LILRB2-Fc to GST-beads or HLA-G6-GST beads
was detected using a PE-conjugated Goat anti-human Fc antibody (Sigma) and flow
cytometric analysis of the resulting beads.
Interaction of HLA-G with membrane-bound LILRB receptors—To investigate the
binding of the HLAG2 and -G6 isoforms to LILRB molecules, NKL-LILRB1+ and NKL-
LILRB1+LILRB2+ cells were incubated in the presence of 1µg/ml of GST or HLA-G6-GST
proteins for 30 min on ice. Cells were then washed and the binding of the recombinant
proteins to the cells was evaluated using FITCconjugated anti-GST antibody (Novus
Biologicals) and flow cytometry analysis
In vivo analysis
Specific pathogen-free C57BL/6 (H-2b) mice and LILRB2-transgenic mice (H-2b) [27] were
used as skin graft recipients throughout the study . Recipient mice received α1–α3-Fc-
coupled microspheres or control microspheres. Donor skin was from MHC class II-disparate
B6.CH-2bm12 (bm12, H-2b) mice. Allogeneic skin grafts were performed by standard
method as described previously [27]. All skin grafting survival data were analysed using
Kaplan Meier survival analysis.
RESULTS
Homodimerization of HLA-G isoforms
In order to demonstrate the dimerization of HLA-G isoforms, we used M8 cells transfected
with HLA-G1 through HLA-G6 isoforms, and their control: M8-pcDNA cells.
Western blot analysis of M8 cell lysates under reducing conditions demonstrated that all the
isoforms were produced and also establishes the size of HLA-G isoform monomers. (Figure
2a). The presence of dimers of HLA-G isoforms was investigated by western blot analysis of
the same cell lysates after electrophoresis under non-reducing conditions (Figure 2b).
Dimers of HLA-G isoforms were easily observed for HLA-G1 and HLA-G5 (α1–α2–α3
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domains, lanes 2 and 6), and HLA-G4 (α1–α2 domains, lane 5). This is the first description
of HLA-G4 homodimers. HLA-G2 and HLA-G6 (α1–α3 domains) were more difficult to
evidence. In the particular experiment shown in Figure 2b, HLA-G2 but not HLA-G6
homodimers were observed (lanes 3 and 7, respectively), although their structure is expected
to be identical. In other experiments, HLA-G6 dimers were evidenced (not shown).
Unexpectedly, homodimers of HLA-G3 (α1 domain, lane 4) were never observed. These
results indicate that the dimerization of HLA-G isoforms is uneven, even though they all
possess the cysteine in position 42, responsible for HLA-G1 and HLA-G5 dimerization [33].
Binding of HLA-G isoforms to LILRB2
Binding to LILRB1 is dependent on B2M association, and thus concerns only B2M-
associated HLA-G1 and HLA-G5 isoforms. However, binding to LILRB2 is not and may
concern HLA-G truncated isoforms. Thus, we investigated the HLA-G isoforms capable of
binding LILRB2 by immunoprecipitation on cell lysates of isoform-transfected M8 cells
(M8pcDNA, M8-HLA-G1, M8-HLA-G2, M8-HLA-G3, M8-HLA-G4, M8-HLA-G5, and
M8-HLA-G6) using LILRB2-Fc-coated beads, followed by anti-HLA-G western blotting.
These results are presented in Figure 3a and show that LILRB2-Fc immunoprecipitated
HLA-G1 and HLA-G5 (α1–α2–α3 domains), and HLA-G2 and HLA-G6 (α1–α3 domains)
but not HLA-G3 (α1 domain). This hinted that LILRB2 recognized only HLA-G isoforms
which contain the α3 domain. However, even though in the experiment shown in Figure 3a
HLA-G4 was not immunoprecipitated, it was in other experiments, yielding to overall
inconclusive data concerning the recognition of this isoforms by LILRB2.
We next focussed on the α1–α3 structure (HLA-G2 and HLA-G6) because it was shown to
be expressed in heart recipient patients who accepted their transplants [12].
First, we used a cytometry-based HLA-G:LILRB interaction analysis to evaluate the binding
of HLA-G2 and -G6 to LILRB1 and LILRB2 using only recombinant proteins. Results are
presented in Figure 3b and show that the HLA-G6-GST recombinant protein was not
recognized by LILRB1-Fc, but was recognized by the LILRB2-Fc protein. These results
confirm the lack of association between HLA-G2 and LILRB1, in accordance with what is
known of the requirement of B2M for LILRB1:HLA-G association. They also confirm the
results obtained by immuno-precipitation.
Second, we investigated the binding of HLA-G6-GST recombinant protein and its GST
control to NKL-LILRB1+ and NKL-LILRB1+LILRB2+ cells. As shown in Figure 3c, HLA-
G6-GST did not bind NKL-LILRB1+ cells, indicating that neither LILRB1 nor KIR2DL4
recognized the α1–α3 structure. On the other hand, NKL-LILRB1+LILRB2+ cells were
strongly positive in this assay, demonstrating that the α1–α3 structure could be recognized
by membrane bound LILRB2, and not only recombinant proteins as in the prior
experiments. The same experiment, conducted for B2M-free GST-HLA-G5 recombinant
proteins, yielded the same results, confirming that B2M-association is required for HLAG5
binding to LILRB1, but not LILRB2.
In vivo analysis
B2M-associated HLA-G1 is capable of delaying skin allograft rejection in a murine animal
model [45,27]. We investigated if the HLA-G α1–α3 structure (HLA-G2 and HLA-G6) also
possessed this function. For this, we used α1–α3-Fc fusion proteins, which were produced in
a different eukaryotic expression system (HeLa cells), and which most of the protein was
present in dimeric form (data not shown). The results obtained for non-transgenic C56BL/6
mice are shown in Figure 4a. As can be seen, one single IP injection of α1–α3-Fc -coated
latex beads 24 hours prior to graft and once again at the time of transplantation, improved
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graft survival. Indeed, the median survival time increased by 5 days, from 18 for control
beads (N=10) to 23 for α1–α3-Fc beads (N=9, p=0.059).
Next, we investigated the tolerogenic function of α1–α3-Fc using LILRB2-transgenic mice
as recipients. Results show that α1–α3-Fc-coated beads significantly increased the graft
median survival time by 6 days, from 17 days for control mice (N=10) to 23 days (N=9,
p=0.0171) (Figure 4b). These results demonstrate that HLA-G α1–α3 isoforms are capable
of increasing graft survival time in both in wild type and transgenic mice, but that it is more
efficient in transgenic mice expressing LILRB2.
DISCUSSION
We based the first part of this work on reports showing that HLA-G1 and HLA-G5 isoforms
associated to B2M form homodimers through a disulphide bond between unique cysteine
residues at position 42 [33], and that LILRB1 and LILRB2 differ in their recognition of
B2M-associated HLA-G1 and HLA-G5, LILRB1 requiring B2M whereas LILRB2 does not
[35,40]. Since these reports concerned only B2M-associated HLA-G1 and HLA-G5
isoforms (α1–α2–α3 domains), we investigated which other isoforms actually formed
dimers, and whether HLA-G2 and HLA-G6 (α1–α3 domains) could function through
LILRB2.
Our results demonstrate that even though all HLA-G isoforms contain the α1 domain and a
cysteine in position 42, they differ in their capability to dimerize. Indeed, as already
reported, dimers of α1–α2–α3 isoforms (HLA-G1 and HLA-G5) were easily detected, and so
were dimers of HLA-G4 (α1–α2 domains). This indicates that for these structures, the C42
residue is indeed free and accessible for disulfide bond formation [35]. The fact that HLA-
G4 behaves as B2M-associated HLA-G1 with respect to dimerization means that the
structures adopted by the α1 and α2 domains of HLA-G1 or -G5 and HLA-G4 are similar,
which is not surprising since these two domains are known to efficiently assemble into the
HLA class I characteristic peptide-binding structure. Hence, C42 is available for
intercellular dimerization for the HLA-G1, HLA-G5 and HLA-G4 isoforms.
Dimers of HLA-G2 and -G6 (α1–α3 domains) and HLA-G3 (α1 domain) were difficult, or
impossible to detect, respectively. This indicates that C42 in these structures may not be
available, or not accessible for dimerization. This may also indicate that, lacking the α2
domain it efficiently assembles with, the α1 domain of HLA-G adopts another, unknown
configuration. In the case of HLA-G2 and - G6, α1 may assemble with α3, or, as the results
obtained for HLA-G3 suggest, may adopt a conformation entirely different, in which no free
cysteine is exposed. In the absence of a crystal structure of HLA-G truncated isoforms, it is
not possible to choose between these two hypotheses. However, the fact that LILRB2
recognizes HLA-G2 and -G6 indicates that the structure of the α3 domain may not be
different between α1–α2–α3 and α1–α3 structures, and so favours the hypothesis of a
different assembly of the α1 domain, and not of a α1–α3 structural association.
The results obtained with HLA-G3 (no dimers) were surprising because we previously
published that a synthetic peptide of the HLA-G alpha1 domain efficiently dimerizes, unlike
HLA-G3 from M8 cells of this study [46]. This indicates that HLA-G dimerization may
depend the cell type that expresses it, and not only on the presence of the alpha1 domain. If
this were proven true, it would mean that the function of HLA-G, which depends on its
dimerization, may be regulated by the cells themselves. We found of particular interest to
study α1–α3 (HLA-G2 and -G6) isoforms since they were detected in the serum of
transplanted patients and their physiological relevance was established [12]. Our results
show that HLA-G2 and -G6 isoforms are recognized by LILRB2 but not LILRB1.
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Moreover, an α1–α3-Fc structure coated on agarose beads, through this interaction, is
tolerogenic in vivo. These results provide the molecular basis for the biological activity of
the HLA-G2 and HLA-G6 isoforms. The fact that these isoforms act through LILRB2 is of
particular interest because this receptor is expressed only by cells of the myeloid lineage, i.e.
monocytes, dendritic cells, macrophages. Thus, unlike B2Massociated HLA-G1 and -G5
isoforms, HLA-G2 and HLA-G6 would not directly act on lymphocytic effectors but on
APC. This is similar to what can be expected of B2M-free HLA-G1 and -G5 isoforms,
which no longer can bind LILRB1. This is also compatible with what is known of the in vivo
model we used. Indeed, in this transplantation model, HLA-G acts chiefly through the PIRB
receptor, which is mainly expressed on APCs.
Taken together, these data clearly show that HLA-G isoforms present important structural
variations which may correspond to different biological functions. As mentioned before,
HLA-G1 and HLA-G5 (α1–α2–α3 associated to B2M) are the most extensively studied
isoforms, probably because of their alleged higher abundance, their availability for in vitro
experiments, and the existence of specific antibodies directed against them. Thus, these
isoforms are believed to be the main isoforms responsible immune regulation in vivo.
However, we do not know to which extent this is true. Isoforms and B2M-free HLA-G
structures may also play a specific role. Not knowing the precise structure of HLA-G
truncated isoforms implies that we do not know which receptors they bind to, either. For
instance, in this work, we studied the HLA-G2 or -G6 interaction with LILRB2 because this
isoform contains the α3 domain and could potentially bind to LILRB2. However, we do not
know what the HLA-G3 receptor could be, or that of HLA-G4, despite our data indicating
that this isoform may bind LILRB2. A recent work [47] describes binding of B2M-
associated and B2M-free forms of MHC to members of the LILR family, and demonstrates
that in addition to LILRB2, B2M-free forms are recognized by several members of the LILR
family. In fact, “activating” members of the LILR family show a preference for these forms.
It is therefore possible that it is also the case for HLA-G. This would support the notion that
HLA-G structural variations may be relevant in biological function modulations. It is also
intriguing to consider that, similarly to classical HLA Class I molecules, HLAG has
activating receptors. Indeed, it is possible that other HLA-G receptors exist, isoform-specific
or not, and studying HLA-G structures other than that of B2M-associated HLA-G1 and -G5
might allow us to identify them. Finally, our data highlight the fact that even though we do
know the physiological importance of HLA-G, we do not know which of its structures are
relevant in vivo.
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Figure 1. HLA-G isoforms
Alternative splicing of HLA-G primary transcript yields 7 isoforms. Excision of one or two
exons encoding globular domain generates truncated isoforms, and translation of intron 4 or
intron 2 yield secreted isoforms that lack the transmembrane domain.
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Figure 2. HLA-G isoforms expression and dimerisation
(a) Monomers of HLA-G isoforms were identified from transfected cell lysates by western
blotting in a reducing SDS-PAGE. (b) Homodimers of HLA-G isoforms were identified
from the same lysates by western blotting in a non-reducing SDS-PAGE. In both cases
4H84, directed toward the HLA-G α1 domain, was used as blotting antibody.
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Figure 3. Recognition of the HLA-G α1–α3 structure by LILRB1
(a) Immunoprecipitation of HLA-G1 and HLA-G5 (α1–α2–α3 domains), and HLA-G2 and
HLA-G6 (α1–α3 domains) with LILRB2-Fc. (b) Differential direct binding of HLA-G6-
GST recombinant protein to LILRB1-Fc and LILRB2-Fc-coated beads (c) Differential
binding of B2M-free HLA-G5-GST and HLA-G6-GST recombinant proteins to NKL-
LILRB1+ and NKL-LILRB1+LILRB2+ cells by flow cytometry analysis, using GST
recombinant protein as control and anti-GST antibody for detection.
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Figure 4. Tolerogenic function of HLA-G α1–α3 structure (α1–α3-Fc) in vivo
C57BL/6 mice strongly recognize the MHC class II-disparate mutant bm12 mouse that
carries the I-A bm12 alloantigen. The capability of α1–α3-Fc-coated beads to delay rejection
was evaluated with non-transgenic and LILRB2-transgenic recipient animals. Kaplan-Meier
curves representing graft survival are shown for α1–α3-Fc (plain lines) and control treatment
(dotted lines) are shown. Control treatment: beads coated with mAb but without α1–α3-Fc.
Results are expressed as Median of graft survival time. Associated values are indicated
above the curves.
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